GlassScriptPhysician profile
Neal Gupta
NPI 1275912552
$2,035.93
in general payments reported to CMS, 2019-2025
19 companies · $605 in 2025
The $605 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.44 · 2020: $54.98 · 2021: $66.92 · 2023: $120 · 2024: $1,167 · 2025: $605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,892.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,891.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $266.16 | 2024-2025 | Sotyktu |
| Janssen Biotech, INC. | $226.36 | 2024 | Tremfya |
| Dermavant Sciences, INC. | $196.21 | 2024 | Vtama |
| Lilly USA, LLC | $178.13 | 2024-2025 | Ebglyss |
| Galderma Laboratories, L.P. | $161.29 | 2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $157.28 | 2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $142.13 | 2025 | |
| Abbvie INC. | $123.47 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $120.21 | 2023 | |
| Ucb, INC. | $110.16 | 2025 | Bimzelx |
| Redhill Biopharma INC. | $73.75 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $66.11 | 2025 | Acthar |
| Organon LLC | $48.59 | 2025 | Vtama |
| Astrazeneca Pharmaceuticals LP | $35.67 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $34.92 | 2019-2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.48 | 2024 | Spevigo |
| Erbe USA INC | $25.00 | 2024 | |
| Novo Nordisk INC | $20.40 | 2025 | Ozempic |
| Biofrontera INC. | $15.61 | 2024 | Xepi, Bf-Rhodoled, Rhodoled Xl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neal Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.